hackint0sh/New-Dataset huggingface dataset:
Participating mother-child dyads in the two intervention arms will receive two sessions of dyadic intervention. Researchers will compare the above-described outcomes between participants in the two intervention arms and the control arm (treatment as usual) to see the effectiveness of the interventions. conditions: HIV conditions: Perinatal HIV Infection studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: PARTICIPANT count: 180 type: ESTIMATED name: Resilience intervention name: Adherence intervention measure: Change of health-related quality of life (HRQoL) measure: Change of depressive and anxiety symptoms measure: Change of resilience factors measure: Change of HAART adherence measure: Change of mediators in the resilience intervention: Perceived stigma measure: Change of mediators in the resilience intervention: Emotional regulation measure: Change of mediators in the resilience intervention: Positive coping measure: Change of mediators in the resilience intervention: Social support measure: Change of mediators in the resilience intervention: Self-efficacy measure: Change of mediators in the adherence intervention: Adherence information, motivation, and behavioral skills measure: Change of mediators in the adherence intervention: Illness perception measure: Change of mediators in the adherence intervention: Adherence efficacy measure: Change of mediators in the adherence intervention: Children's medication-taking responsibility measure: Change of mother-child relationship and interaction: Dyadic coping measure: Change of mother-child relationship and interaction: Mother-child closeness measure: Change of mother-child relationship and interaction: Family harmony measure: Change of mother-child relationship and interaction: Mother-child conflict measure: Change of mother-child relationship and interaction: Relationship satisfaction sex: ALL minimumAge: 10 Years maximumAge: 17 Years stdAges: CHILD facility: Guangxi Center for Disease Prevention and Control status: RECRUITING city: Nanning state: Guangxi zip: 530027 country: China name: Xiaoliang Zeng, Dr. role: CONTACT phone: +86 13457089643 email: 41045926@qq.com lat: 22.81667 lon: 108.31667 hasResults: False
nctId: NCT06340685 id: STUDY23050042 id: UX007-IST236 type: OTHER_GRANT domain: Ultragenyx Pharmaceutical Inc. briefTitle: Triheptanoin for Children With Primary-Specific Pyruvate Dehydrogenase Complex (PDC) Deficiency overallStatus: RECRUITING date: 2024-05 date: 2026-12-31 date: 2027-06-30 date: 2024-04-01 date: 2024-04-04 name: Jirair Krikor Bedoyan class: OTHER name: Ultragenyx Pharmaceutical Inc briefSummary: This is a medical research study to test a medication in patients with a disease called Pyruvate Dehydrogenase Complex (PDC) Deficiency. The medication is triheptanoin, which is currently FDA approved for the treatment of Long-Chain Fatty Acid Oxidation Disorders. Previous research suggests that triheptanoin may also be effective in the treatment PDC Deficiency. This study will investigate the safety and efficacy (how well it works) of triheptanoin in patients with PDC Deficiency. conditions: Pyruvate Dehydrogenase Complex Deficiency studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 6 type: ESTIMATED name: Triheptanoin measure: Number of participants who report side-effects related to gastrointestinal (GI) distress measure: Normalization of biochemical markers of disease (lactate) measure: Normalization of biochemical markers of disease (pyruvate) measure: Normalization of biochemical markers of disease (β-hydroxybutyrate level) measure: Normalization of biochemical markers of disease (Alanine/Leucine ratio) measure: Normalization of biochemical markers of disease (Alanine/Lysine ratio) measure: Normalization of biochemical markers of disease (Alanine/Proline ratio) measure: More efficacious seizure control measure: More efficacious metabolic control measure: More efficacious disease control measure: Improved quality of life measure: Improved long-term maintenance and tolerance of diet measure: Improved quality of life sex: ALL minimumAge: 1 Year maximumAge: 17 Years stdAges: CHILD facility: UPMC Children's Hospital of Pittsburgh status: RECRUITING city: Pittsburgh state: Pennsylvania zip: 15224 country: United States name: Danielle Black, MPH role: CONTACT phone: 412-692-6893 email: danielle.black@chp.edu name: Jirair Bedoyan, MD, PhD role: PRINCIPAL_INVESTIGATOR lat: 40.44062 lon: -79.99589 hasResults: False
nctId: NCT06340672 id: STUDY24010034 briefTitle: The Effect of AR in Patient Pre-operative Education overallStatus: NOT_YET_RECRUITING date: 2024-04-15 date: 2025-02-01 date: 2025-02-01 date: 2024-04-01 date: 2024-04-01 name: University of Pittsburgh class: OTHER briefSummary: The purpose of this clinical trial is to analyze the effect of augmented reality (AR) on patient education and overall satisfaction when used during preoperative counseling in older adults undergoing spinal surgery. The main aims of this study are:
This study will compare AR enhanced preoperative patient counseling with conventional preoperative counseling practices. conditions: Anterior Cervical Discectomy and Fusion conditions: Transforaminal Lumbar Interbody Fusion studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: NONE count: 100 type: ESTIMATED name: Augmented Reality Enhanced Preoperative Counseling name: Standard preoperative counseling measure: Amsterdam Preoperative Anxiety and Information Score (APAIS) survey measure: Simulator Sickness Questionnaire (SSQ) measure: Evaluation of the Experience of General Anesthesia (EVAN-G) Survey measure: Time of preoperatively patient counseling measure: Degree of knowledge acquisition questionnaire at baseline measure: Degree of knowledge acquisition questionnaire 2 weeks post-operative measure: Degree of knowledge acquisition questionnaire 3 months post-operative measure: Degree of knowledge acquisition questionnaire 6 months post-operative measure: Participant age measure: Participant gender measure: Participant's indication for surgery measure: Participant education measure: Participant's past surgeries measure: Names of pain medications measure: Doses of pain medications measure: Prior experience with simulated environments measure: Patient understanding of surgery at baseline measure: Patient understanding of surgery 2 weeks post-operative measure: Patient understanding of surgery 3 months post-operative measure: Patient understanding of surgery 6 months post-operative measure: Patient pain level at baseline measure: Patient pain level 2 weeks post-operatively measure: Patient pain level 3 months post-operatively measure: Patient pain level 6 months post-operatively measure: Confidence in surgeon at baseline measure: Confidence in surgeon 2 weeks post-operatively measure: Confidence in surgeon 3 months post-operatively measure: Confidence in surgeon 6 months post-operatively measure: Patient preoperative visit satisfaction level measure: Patient satisfaction level with the surgical explanation at baseline measure: Patient postoperative visit satisfaction level 2 weeks post-operatively measure: Patient surgery satisfaction level 2 weeks post-operatively measure: Patient postoperative visit satisfaction level 3 months post-operatively measure: Patient surgery visit satisfaction level 3 months post-operatively measure: Patient postoperative visit satisfaction level 6 months post-operatively measure: Patient surgery satisfaction level 6 months post-operatively measure: Patient referral rates measure: Patient retention rates measure: Patient preference on the type of pre-operative counseling received for the AR-specific participants sex: ALL minimumAge: 65 Years stdAges: OLDER_ADULT facility: University of Pittsburgh Medical Center city: Pittsburgh state: Pennsylvania zip: 15213 country: United States name: Edward Andrews, MD role: CONTACT phone: 412-232-5666 email: andrewse2@upmc.edu name: Edward Andrews, MD role: PRINCIPAL_INVESTIGATOR lat: 40.44062 lon: -79.99589 hasResults: False
nctId: NCT06340659 id: AE and CT briefTitle: Concurrent Aerobic Exercise and Cognitive Training to Prevent Alzheimer's in At-risk Older Adults (The Exergames Telerehabilitation Study) overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2027-07-01 date: 2027-07-01 date: 2024-04-01 date: 2024-04-01 name: University of Minnesota class: OTHER briefSummary: Significance of Research Question/Purpose: Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the AD-dementia continuum and currently has a prevalence of 11.2% in adults over the age of 45, with incidence increasing with greater age. Furthermore, population-based studies suggest that between 50% and 80% of older individuals (aged 70 years and older) who perform normally on cognitive tests, report some form of perceived decline in cognitive functioning when asked. The SCD state is unique as this population is more likely than their healthy peers to present with AD biomarkers such as neurodegeneration and amyloid burden, and therefore represents probable preclinical AD relative to other causes of SCD. Likewise, growing evidence suggests that a significant proportion of those adults are subsequently found to develop MCI, or AD, following the classic SCD-MCI-AD trajectory, with SCD increasing MCI risk 1.5-3 fold. Preventing Alzheimer's disease (AD) is arguably the most important approach to address the dementia epidemic worldwide because 99.6% of drug trials failed and no drugs can yet prevent, cure, or even slow AD. A treatment that delays the onset of AD by five years could save $89 billion in 2030.This highlights an urgent and pressing need to develop behavioral interventions to prevent AD and slow its progression.
The first purpose is to develop a fully-featured version of the Virtual Reality Cognitive Training (VRCT) aspect of the Exergame that can be installed and updated remotely. We will build on the Phase II Exergame by creating the capability that allows it to be installed and updated remotely to facilitate home-based use, especially by older adults. This also helps address a strong preference from our Phase II participants to minimize interaction with outsiders due to the ongoing COVID-19 pandemic, indicating a home- based solution will greatly facilitate commercialization. The second purpose is to determine the efficacy of the Home-based (Hb)Exergame on cognition and aerobic fitness in older adults at risk for AD using a 2:2 factorial design clinical trial. We will measure the following outcomes quantitatively: a) cognition: fluid cognition (global cognition) as the primary outcome, processing speed and other cognitive domains as secondary outcomes; b) aerobic fitness, c) neuroprotective blood biomarkers. conditions: AD-dementia studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: RANDOMIZED interventionModel: FACTORIAL interventionModelDescription: This study will use a single-blind, randomized, 2:2 factorial design. will randomize 104 community-dwelling older adults to one of four arms for 3 months: home-based (asynchronous) Exergame (HbExergame), supervised Exergame, home-based asynchronous aerobic exercise (HbAEx, or supervised aerobic exercise (supervised AEx). Randomization will allocate subjects on a 1:1:1:1 allocation ratio within each age stratum (65-74 and ≥75) in random blocks of 8 or 4 primaryPurpose: SUPPORTIVE_CARE masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 104 type: ESTIMATED name: Supervised AEx name: HbAEx name: Supervised Exergame name: HbExergame measure: fluid cognition (global cognition) measure: Cognitive Function measure: Aerobic fitness measure: Neuroprotective biomarkers and ApoE status. measure: Exergame-specific usability and satisfaction measure: Standing balance measure: Four-meter walking velocity measure: Repeated chair raise measure: Quality of Life (QoL) measure: SCD Symptoms sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06340633 id: SPI-1005-261 briefTitle: SPI-1005 in Adults Receiving Cochlear Implant overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2025-12 date: 2025-12 date: 2024-04-01 date: 2024-04-01 name: Sound Pharmaceuticals, Incorporated class: INDUSTRY name: Med-El Corporation briefSummary: The goal of this clinical trial is to learn about the effects of drug SPI-1005 in adults receiving a cochlear implant with a long electrode array (FLEX26 or greater) from MED-EL Cochlear Implant Systems into one ear.
The effects of SPI-1005 will be compared to the placebo (the look-alike substance that contains no drug) to study what effects SPI-1005 might have. conditions: Hearing Loss conditions: Cochlear Trauma studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 40 type: ESTIMATED name: Ebselen name: Placebo measure: Number of Participants with Treatment Emergent Adverse Events (TEAE) measure: Effect of SPI-1005 on Residual Low Frequency Hearing measure: Effect of SPI-1005 on Word Recognition measure: Effect of SPI-1005 on Speech Discrimination measure: Effect of SPI-1005 on Tinnitus measure: Effect of SPI-1005 on Vertigo sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06340620 id: 24.017.01 briefTitle: EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope overallStatus: RECRUITING date: 2024-03-25 date: 2026-12 date: 2027-12 date: 2024-04-01 date: 2024-04-01 name: Orlando Health, Inc. class: OTHER briefSummary: This is a randomized trial to compare the standard echoendoscope with the newly developed EndoSound Visual System in the evaluation of lesions in the gastrointestinal tract. conditions: Pancreatic Disease conditions: Pancreatic Cancer conditions: Pancreatic Cyst conditions: Gastrointestinal Tumor conditions: Bile Duct Diseases conditions: Bile Duct Cancer conditions: Lymph Node Disease conditions: Submucosal Tumor of Gastrointestinal Tract conditions: Gastrointestinal Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: DIAGNOSTIC masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 140 type: ESTIMATED name: Endoscopic ultrasound examination measure: Rate of successful completion of the requisite EUS examination measure: Ease of maneuverability of the device measure: Quality of EUS imaging measure: Ease of performing tissue acquisition measure: Diagnostic adequacy of procured specimen on onsite evaluation measure: Diagnostic adequacy of procured specimen in cell block measure: Diagnostic accuracy of procured specimen measure: Procedure duration measure: Rate of procedure-related adverse events measure: Procedure costs sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Orlando Health status: RECRUITING city: Orlando state: Florida zip: 32806 country: United States name: Ji Young Bang, MD MPH role: CONTACT phone: 321-841-2431 email: jiyoung.bang@orlandohealth.com name: Barbara Broome role: CONTACT phone: 321-841-4356 email: barbara.broome@orlandohealth.com lat: 28.53834 lon: -81.37924 hasResults: False
nctId: NCT06340607 id: 2023-0561 briefTitle: Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients overallStatus: COMPLETED date: 2012-01-05 date: 2020-01-05 date: 2022-12-31 date: 2024-04-01 date: 2024-04-01 name: Asan Medical Center class: OTHER briefSummary: This study investigates the association between post-reperfusion (neohepatic) ALBI scores and post-LT renal outcomes in living-donor LT (LDLT) recipients. conditions: Acute Kidney Injury conditions: Chronic Kidney Diseases conditions: Graft Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 3422 type: ACTUAL measure: acute kidney injury measure: chronic kidney injury measure: graft failure sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Asan Medical Center city: Seoul state: Song-pa Gu zip: 05500 country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06340594 id: RF-2-2024 briefTitle: Single-stage ERCP and Laparoscopic Cholecystectomy for Cholecystocholedocholithiasis: Which to Start With? overallStatus: COMPLETED date: 2021-01-01 date: 2023-12-01 date: 2024-01-30 date: 2024-04-01 date: 2024-04-02 name: Assiut University class: OTHER briefSummary: Chronic calculous cholecystitis is associated with common bile duct (CBD) stones in approximately 12% of patients. These patients need both cholecystectomy and CBD clearance of stones. The standard for cholecystectomy is laparoscopic cholecystectomy (LC) and the mostly common treatment used for CBD clearance is Endoscopic Retrograde Cholangiopancreatography (ERCP). The two interventions can be combined to be done at the same time under single anesthesia session. Studies of single stage ERCP+LC showed confirmed the safety and efficacy of the combined technique. However, some surgeons start with the ERCP while others start with LC.The aim of this study is to compare the start with ERCP followed by LC to the start with LC followed by ERCP when the two techniques are combined at the same session for treatment of chronic calculous cholecystitis associated with CBD stones regarding efficacy and safety of the two approaches. conditions: Choledocholithiasis With Cholecystitis conditions: Biliary Stones studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 115 type: ACTUAL name: Laproscopic cholecystectomy (LC) name: Endoscopic Retrograde Cholangiopancreatography (ERCP) measure: Operative time operative time measure: CBD clearance rate measure: Length of hospital stay measure: Mortality rate sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Medicine-Assiut University -Assiut-Egypt city: Assiut state: Asyut zip: 71515 country: Egypt lat: 27.18096 lon: 31.18368 hasResults: False
nctId: NCT06340581 id: D5985C00009 id: 2023-509914-12 type: OTHER domain: EU CT briefTitle: A Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, & Formoterol (BGF) Metered Dose Inhaler (MDI) Hydrofluoroolefin (HFO) With a Spacer (Treatment B), BGF MDI Hydrofluoroalkane (HFA) With a Spacer (Treatment A), as Well as BGF MDI HFO Without a Spacer (Treatment C). overallStatus: NOT_YET_RECRUITING date: 2024-06-17 date: 2024-10-28 date: 2024-10-28 date: 2024-04-01 date: 2024-04-01 name: AstraZeneca class: INDUSTRY name: Parexel briefSummary: The purpose of this study is to assess the bioequivalence of the lung exposure of budesonide, glycopyrronium, and formoterol administered as budesonide, glycopyrronium, formoterol (BGF) metered dose inhaler (MDI) hydrofluoroolefin (HFO) with AeroChamber Plus Flow-Vu spacer compared with BGF MDI hydrofluoroalkane (HFA) with AeroChamber Plus Flow Vu spacer And BFG MDI HFO (Spacer vs No Spacer). conditions: Healthy studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 132 type: ESTIMATED name: Treatment A: BGF MDI HFA name: Treatment B: BGF MDI HFO name: Treatment C: BGF MDI HFO name: AeroChamber Plus Flow-Vu Spacer measure: Area Under the Plasma Concentration-curve from Zero to the Last Quantifiable Concentration (AUClast) of BGF MDI measure: Maximum Observed Concentration (Cmax) of BGF MDI measure: Area Under the Plasma Concentration-curve from Zero to the Last Quantifiable Concentration (AUClast) measure: Maximum Observed Concentration (Cmax) measure: Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUCinf) measure: Time to Reach Maximum Observed Concentration (tmax) measure: Terminal Rate Constant (λz) measure: Half-life Associated with Terminal Slope (λz) of a Semi-logarithmic Concentration-time Curve (t1/2λz) measure: Mean Residence Time of the Unchanged Drug in the Systemic Circulation from Zero to Infinity (MRTinf) measure: Apparent Total Body Clearance of Drug from Plasma After Extravascular Administration (CL/F) measure: Apparent Volume of Distribution at Steady State Following Extravascular Administration (Vz/F) measure: Number of Participants with Adverse Events sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
nctId: NCT06340568 id: BNT323-01 id: GOG-3105 type: OTHER domain: GOG foundation id: 2023-507525-42-00 type: OTHER domain: EU CT id: ENGOT- en25/NSGO-CTU type: OTHER domain: European Network for Gynaecological Oncological Trial groups (ENGOT) briefTitle: A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-10 date: 2028-08 date: 2024-04-01 date: 2024-04-01 name: BioNTech SE class: INDUSTRY name: DualityBio Inc. briefSummary: The goal of this clinical study is to assess the efficacy of BNT323/DB-1303 compared with investigator's choice of chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the endometrial cancer population. conditions: Endometrial Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 468 type: ESTIMATED name: BNT323/DB-1303 name: Doxorubicin name: Paclitaxel measure: PFS by BICR in the endometrial cancer population measure: Overall survival (OS) in the endometrial cancer population measure: PFS assessed by the investigator in the endometrial cancer population measure: Objective response rate (ORR) in the endometrial cancer population measure: Duration of response (DoR) in the endometrial cancer population measure: Number of patients with occurrence of treatment-emergent adverse events (TEAEs) measure: Number of patients with occurrence of dose reduction, delay, and discontinuation of study treatments due to TEAEs sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06340555 id: PIC-156-22 briefTitle: Intervention to Prevent Mental Health Disorders of Women and Their Partners Who Experienced Pregnancy Loss acronym: Enzo overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-01 date: 2024-12-31 date: 2025-07-31 date: 2024-04-01 date: 2024-04-01 name: Fundació Sant Joan de Déu class: OTHER name: University of Barcelona name: University of Seville briefSummary: The goal of this clinical trial is to test impact of a multiprofessional intervention in mothers and partners who suffer a pregnancy loss. The main questions it aims to answer are:
Researchers will compare with mothers with standard care to see if the multiprofessional intervention has an impact. conditions: Stillbirth and Fetal Death studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 120 type: ESTIMATED name: GUIA ATENCION MULTIDISCIPLINAR SANT BOI name: USUAL CARE measure: Intensity of grief measure: Depressive symptoms measure: Anxiety symptoms measure: Perinatal postraumatic stress disorder sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Parc Sanitari Sant Joan de Deu city: Sant Boi De Llobregat state: Barcelona zip: 08830 country: Spain lat: 41.34357 lon: 2.03659 hasResults: False